Skip to main content
OpenTrials

Clinical trial condition

Paroxysmal Nocturnal Hemoglobinuria

Explore clinical trials studying Paroxysmal Nocturnal Hemoglobinuria. Study availability and eligibility vary by location and protocol.

92 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Paroxysmal Nocturnal Hemoglobinuria trial results

Active, not recruiting

Specified Drug-use Surveillance of Fabhalta Capsules

NCT06606314

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Hachinohe, Aomori, Japan
  • Novartis Investigative Site Chiba, Japan
  • Novartis Investigative Site Aizu-Wakamatsu, Fukushima, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
View all 91 locations
View Trial Details
Active, not recruiting

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Liverpool Hospital Liverpool, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Sunshine Coast University Hospital Birtinya, Queensland, Australia
  • Canberra Hospital Garran, Australia
View all 87 locations
View Trial Details
Active, not recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

NCT04654468

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • West China Hospital, Sichuan University Chengdu, China
  • Guangdong General Hospital Guangzhou, China
  • Institute of Hematology and Hospital of Blood Disease Tianjin, China
  • Tianjin Medical University General Hospital Tianjin, China
View Trial Details
Active, not recruiting

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Organizacion Medica de Investigacion (OMI) Ciudad Autonoma Buenos Aires, Argentina
  • *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia Santo André, São Paulo, Brazil
  • Beneficencia Portuguesa de Sao Paulo São Paulo, Brazil
  • Peking Union Medical College Hospital Beijing, China
View all 63 locations
View Trial Details
Active, not recruiting

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04747613

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • City Of Hope National Med Center Duarte, California, United States
  • City Of Hope Duarte, California, United States
  • USC Norris Cancer Center Los Angeles, California, United States
  • Univ Cali Irvine ALS Neuromuscular Orange, California, United States
View all 60 locations
View Trial Details
Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

NCT04432584

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Carolinas Healthcare System Charlotte, North Carolina, United States
  • Nationwide Children's Hospital Columbus, Ohio, United States
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • AZ Delta Campus Westlaan Roeselare, Belgium
View all 80 locations
View Trial Details
Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Baltimore, Maryland, United States
  • Research Site Kansas City, Missouri, United States
View all 45 locations
View Trial Details

Related conditions